1. Home
  2. MESO vs FORTY Comparison

MESO vs FORTY Comparison

Compare MESO & FORTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • FORTY
  • Stock Information
  • Founded
  • MESO 2004
  • FORTY 1985
  • Country
  • MESO Australia
  • FORTY Israel
  • Employees
  • MESO N/A
  • FORTY N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • FORTY EDP Services
  • Sector
  • MESO Health Care
  • FORTY Technology
  • Exchange
  • MESO Nasdaq
  • FORTY Nasdaq
  • Market Cap
  • MESO 1.1B
  • FORTY 1.2B
  • IPO Year
  • MESO N/A
  • FORTY 1997
  • Fundamental
  • Price
  • MESO $10.18
  • FORTY $82.73
  • Analyst Decision
  • MESO Strong Buy
  • FORTY
  • Analyst Count
  • MESO 4
  • FORTY 0
  • Target Price
  • MESO $11.50
  • FORTY N/A
  • AVG Volume (30 Days)
  • MESO 215.6K
  • FORTY 606.0
  • Earning Date
  • MESO 08-28-2024
  • FORTY 11-21-2024
  • Dividend Yield
  • MESO N/A
  • FORTY 1.52%
  • EPS Growth
  • MESO N/A
  • FORTY 18.72
  • EPS
  • MESO N/A
  • FORTY 4.83
  • Revenue
  • MESO $5,902,000.00
  • FORTY $2,706,303,000.00
  • Revenue This Year
  • MESO $66.05
  • FORTY N/A
  • Revenue Next Year
  • MESO $348.27
  • FORTY N/A
  • P/E Ratio
  • MESO N/A
  • FORTY $17.31
  • Revenue Growth
  • MESO N/A
  • FORTY 2.60
  • 52 Week Low
  • MESO $1.61
  • FORTY $58.29
  • 52 Week High
  • MESO $12.18
  • FORTY $87.70
  • Technical
  • Relative Strength Index (RSI)
  • MESO 54.91
  • FORTY 52.79
  • Support Level
  • MESO $10.00
  • FORTY $77.50
  • Resistance Level
  • MESO $10.98
  • FORTY $82.83
  • Average True Range (ATR)
  • MESO 0.59
  • FORTY 0.42
  • MACD
  • MESO 0.06
  • FORTY -0.49
  • Stochastic Oscillator
  • MESO 47.92
  • FORTY 51.27

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources; Michpal; ZAP Group and Others. The majority of the company's revenue comes from Israel.

Share on Social Networks: